CMV

Moderna (Nasdaq:MRNA) recently announced that an investigational version of its COVID-19 vaccine for potential use in children 6 months to 6 years met its primary endpoint in a Phase 2/3 study. Two doses of the vaccine were 43.7% effective at preventing infection during the omicron wave in children aged 6 months to 2 years old.…

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) has announced that it has published data from the SOLSTICE Phase 3 trial for Livtencity (maribavir) in post-transplant recipients with cytomegalovirus (CMV) infection in the peer-reviewed journal of Clinical Infectious Diseases. The drug was statistically superior to conventional therapies at week 81. The trial met its primary endpoint. A total of 55.7%…

FDA has approved Takeda Pharmaceutical’s (NYSE:TAK) Livtencity (maribavir) for use in patients at least 12 years old with post-transplant cytomegalovirus (CMV) infection or disease that does not respond to available antiviral therapy. The indication covers patients weighing at least 35 kilograms. Livtencity blocks virus replication by blocking the activity of the human cytomegalovirus enzyme pUL97.…

Moderna CEO Stéphane Bancel has stressed that the company is not just a COVID-19 vaccine maker. Now, Cambridge, Massachusetts–based Moderna (NSDQ:MRNA) has announced that its mRNA-based cytomegalovirus (CMV) vaccine candidate is entering a Phase 3 pivotal registration study. “Moderna has been focusing on a vaccine against CMV for a number of years,” said Lori Panther,…

COVID-19 vaccines launched BioNTech and Moderna into the limelight, making these once little-known companies prominent companies. But neither wants to be pigeonholed as a COVID-19 vaccine company. BioNTech cofounder Özlem Türeci stressed in a recent interview with AP that the mRNA vaccine technology that is its focus could be a powerful weapon against cancer. “We have several different…